Today's Date: June 20, 2024
#1 SPORT FOR OLYMPIC AUDIENCES AND FEMALE FANS FINDS FIELD OF PLAY WITH GLOBAL IMPACT GYMNASTICS ALLIANCE (GIGA)   •   Peruvian Trade Set for Boost as DP World Completes $400M Callao Port Expansion   •   Hebrew SeniorLife's Jack Satter House to Receive Up To $20 Million HUD Grant to Support Energy Efficiency and Climate Resilience   •   Ahead of the Second Anniversary of the Overturn of Roe v. Wade, New IWPR Analysis Shows State Abortion Bans Cost the US Economy   •   Cambium Learning Group Releases 2023 Impact Report Highlighting Its Commitment to Addressing the Most Critical Needs of K-12 Stu   •   LA Kings Unveil Brand Evolution   •   More than 1,000 Florida adolescents will learn about emotional intelligence thanks to the partnership between the Ismael Cala Fo   •   Healthy meals for our kids   •   Netflix’s ‘Toughest Forces on Earth’ Host and Former British Special Forces Soldier Dean Stott Receives MBE   •   National Beverage Corp. Announces LaCroix Partnership with Inter Miami CF   •   Vizient examines pulsed field ablation, wearables for women’s cardiovascular health in latest Medical Device Tech Watch   •   Wayfinder Family Services Earns Highest Possible Rating from Charity Navigator   •   SNOOP DOGG'S DR. BOMBAY PARTNERS WITH BOYS & GIRLS CLUB LONG BEACH, PITTSBURGH AND PORTLAND TO PROVIDE ICE CREAM SOCIALS &am   •   Beazer Homes USA, Inc. Announces the Release of its 2023 Sustainability Report   •   Five Startups Announced in 2024 Remarkable US Accelerator Program   •   Envision Energy Releases 2024 Net Zero Action Report Highlighting Global Decarbonization Achievements   •   Sal Mian, represented by Rob Wiley, P.C., files disability discrimination lawsuit against Thermotech Insulation Co. LLC   •   AHF Helps Shore Up HIV Care in Pierce County   •   Arch Insurance to Host Webinar on New Paid Family and Medical Leave Programs in Delaware, Maine, Maryland and Minnesota   •   Molina Healthcare of New Mexico Supporting Residents Impacted By New Mexico Wildfires
Bookmark and Share

Materna Medical Completes First Close of Series B2 Financing Round

MOUNTAIN VIEW, Calif. , May 23 /Businesswire/ - Materna Medical, Inc., a leading innovator in women's pelvic health solutions, has announced the completion of the first close of a $20 million Series B2 financing round. The round was led by InnovaHealth Partners and other key existing investors included Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, Golden Seeds, Band of Angels, and Houston Angel Network.

"Materna is a first mover, aiming to transform the standard of care in labor and delivery. Imagine a world in which women aren’t injured while delivering vaginally," commented Tracy MacNeal, Chief Executive Officer for Materna Medical. "Our nation’s maternal health crisis is a clarion call for new obstetrical technologies, and Materna is leading the way."

The company has successfully reached several key milestones, including obtaining over-the-counter FDA clearance for its first commercial product, the Milli Vaginal Dilator. Additionally, clinical data from an expanded feasibility study of Materna’s second product, Materna Prep, shows substantial promise in the potential to reduce pelvic floor injury rates for women delivering vaginally.

Dr. Ariella Golomb, Materna’s Board Chair and Partner at InnovaHealth Partners added, "We are pleased with the Company’s progress, excited about the feasibility data and look forward to its publication later this year. The funds from Series B2 will be used to obtain FDA marketing authorization for Materna Prep and support the commercial launch of this transformative technology.”

For more information on Materna Medical, visit

About Materna Medical

Materna Medical is a novel OBGYN platform company defining a $6B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health.

Our first product, Milli, is vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes are being studied in a post-market prospective virtual study named POMPOM.

Materna’s second product, Materna Prep, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial running in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.

STORY TAGS: Medical Devices, Health, Consumer, Women, Health Technology, General Health, United States, North America, California, Funding,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News